title: [New combination of epirubicine, bleomycin, vinblastine and prednisone (EBVP II) before radiotherapy in localized stages of Hodgkin's disease. Phase II trial in 50 patients].
abstract: A new regimen of chemotherapy was used to reduce toxicity of EBVP I: the number of injections and the doses of bleomycin and vinblastine were reduced by half, the duration of treatment by third. Fifty patients with Hodgkin's disease stage I to IIIA, previously untreated, received three courses of this regimen before radiotherapy. Gastro-intestinal toxicity was similar and alopecia was more marked than with EBVP I. Immediate efficacy is similar, with 90% of complete remission and only one failure. This regimen is shorter and more intensive than EBVP I. It deserves larger comparison with previously used chemotherapy in a more extensive controlled trial.
authors: Fondation Bergonie, Bordeaux.
authors: B
authors: B
authors: Hoerni
authors: M B
authors: MB
authors: Orgerie
authors: H
authors: H
authors: Eghbali
authors: C M
authors: CM
authors: Blanc
authors: B
authors: B
authors: David
authors: J
authors: J
authors: Rojouan
authors: R
authors: R
authors: Zittoun
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001761:Bleomycin; D015251:Epirubicin; D014747:Vinblastine; D011241:Prednisone
vernacular_title: Nouvelle association d'épirubicine, bléomycine, vinblastine et prednisone (EBVP II) avant radiotherapie dans les stades localisés de maladie de Hodgkin. Essai de phase II chez 50 malades.